By Sidney Taiko Sheehan
Just last year, Danny JJ Wang, PhD, Co-Founder and Chief Science Officer of Hura Imaging, Inc., and Director of Imaging Technology Innovation at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (USC INI), and his team received a two-year $1.6 million grant from the National Institutes of Health’s Small Business Innovation Research (SBIR). The SBIR program supports the translation of technologies from the lab to commercial use through small business innovation and commercialization.
Dr. Wang and his team are addressing the growing concern that radiation involved in computed tomography (CT) scans can be unnecessarily harmful to patients. CT scans can certainly save lives by catching abnormalities, but there is a strong desire for methods that can lower the risk of cancer with reduced use of radiation. However, low dose CT scans result in low contrast or noisy images.
“Our technology reduces the image noise of CT perfusion and improves image contrast by about 50-75% without compromising imaging speed,” says Dr. Wang. “Compared to existing low-dose CT technologies, our technique has the advantages of fast computation speed and excellent retention of the texture and resolution of CT images. We are delighted to report that we have now received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our CT perfusion software (Hura CTPTM).”
“Dr. Wang’s technique dramatically improves the quality and signal-to-noise ratio of CT perfusion images, with minimal additional computation time,” says Vinay Duddalwar, MD, Professor of Clinical Radiology at the Keck School of Medicine. “The technology may impact the safety and clinical practice of CT perfusion.” Dr. Duddalwar is the lead investigator of the SBIR study at the Keck School of Medicine at USC.
FDA 510(k) clearance is a critical and necessary step when preparing a “device” for market in the U.S. “We set out with the goal to make CT scans safer while improving image quality,” says Jeffry Alger, PhD, Senior Scientist at Hura Imaging and Professor Emeritus at the David Geffen School of Medicine at UCLA. “We are now one step closer to commercializing this work so that it can be widely used in clinical practice to help keep patients safe while improving the quality of clinical care.”
Hura Imaging was established in 2017, and received NIH SBIR phase 1 and 2 funding as well as angel investor Leo Wang. Currently Hura Imaging is collaborating with the USC INI and USC’s Radiology Department, University of Texas Southwestern Medical Center, and Weill Cornell Medicine. The INI provides the facilities and computational resources through its Laboratory of Neuro Imaging (LONI) and Hura Imaging is handling commercialization of the technology. “I’m grateful for the opportunity to impact translational research and to celebrate this milestone with my colleagues,” says Dr. Wang.